D.A. Davidson & Co. Madrigal Pharmaceuticals, Inc. Transaction History

D.A. Davidson & Co.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$193.33 - $291.99 $138,230 - $208,772	715 New	715 $200,000
Q4 2022 Feb 03, 2023	BUY	$58.39 - $296.54 $42,040 - $213,508	720 New	720 $208,000
Q1 2019 May 13, 2019	SELL	$103.48 - $143.84 $183,677 - $255,316	-1,775 Closed	0 $0
Q4 2018 Jan 29, 2019	SELL	$94.77 - $215.54 $15,163 - $34,486	-160 Reduced 8.27%	1,775 $200,000
Q3 2018 Nov 13, 2018	SELL	$207.3 - $300.31 $1,036 - $1,501	-5 Reduced 0.26%	1,935 $414,000
Q2 2018 Aug 02, 2018	SELL	$101.55 - $313.9 $101,042 - $312,330	-995 Reduced 33.9%	1,940 $543,000
Q1 2018 May 04, 2018	SELL	$93.35 - $149.04 $80,747 - $128,919	-865 Reduced 22.76%	2,935 $343,000
Q4 2017 Feb 08, 2018	BUY	$39.35 - $97.37 $149,530 - $370,006	3,800 New	3,800 $349,000
Q3 2017 Nov 08, 2017	SELL	$15.48 - $46.19 $61,146 - $182,450	-3,950 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	3,950	3,950 $0

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.